Posted by Michael Wonder on 01 Jan 2022
Paion submits extension application of marketing authorisation for remimazolam in the indication general anaesthesia to the European Medicines Agency
31 December 2021 - Paion today announces that it has submitted an extension application to the marketing authorisation for remimazolam (Byfavo), Paion's ultra-short-acting intravenous benzodiazepine sedative/anaesthetic, for the indication general anaesthesia to the EMA.
Based on the positive results in the EU Phase 3 trial in general anaesthesia, Paion has now submitted an extension application to the marketing authorisation for remimazolam in the indication of general anaesthesia.
